Journal
JOURNAL OF CLINICAL UROLOGY
Volume 5, Issue 4, Pages 162-168Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1016/j.bjmsu.2011.08.006
Keywords
Prostatic neoplasms; Prostate specific antigen
Categories
Funding
- NCI NIH HHS [P50 CA092629-08, P50 CA092629] Funding Source: Medline
Ask authors/readers for more resources
Cancer is a growth process and it is natural that we should be concerned with how the routinely used marker of prostate cancer tumour burden PSA - changes over time. Such change is measured by PSA velocity or PSA doubling time, described in general as PSA kinetics''. However, it turns out that calculation of PSA velocity and doubling time is far from straightforward. More than 20 different methods have been proposed, and many of these give quite divergent results. There is clear evidence that PSA kinetics are critical for understanding prognosis in advanced or relapsed prostate cancer. However, PSA kinetics have no value for men with an untreated prostate: neither PSA velocity nor doubling time have any role in diagnosing prostate cancer or providing a prognosis for men before treatment. (C) 2011 British Association of Urological Surgeons. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available